BR9611410A - Método e composição farmacêutica para regular a concentração de lipídios - Google Patents

Método e composição farmacêutica para regular a concentração de lipídios

Info

Publication number
BR9611410A
BR9611410A BR9611410A BR9611410A BR9611410A BR 9611410 A BR9611410 A BR 9611410A BR 9611410 A BR9611410 A BR 9611410A BR 9611410 A BR9611410 A BR 9611410A BR 9611410 A BR9611410 A BR 9611410A
Authority
BR
Brazil
Prior art keywords
lipids
regulate
concentration
composition
pharmaceutical method
Prior art date
Application number
BR9611410A
Other languages
English (en)
Inventor
Thomas M A Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611410(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9611410A publication Critical patent/BR9611410A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BR9611410A 1995-11-02 1996-10-02 Método e composição farmacêutica para regular a concentração de lipídios BR9611410A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02
PCT/US1996/015854 WO1997016184A1 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Publications (1)

Publication Number Publication Date
BR9611410A true BR9611410A (pt) 1999-01-05

Family

ID=21719566

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611410A BR9611410A (pt) 1995-11-02 1996-10-02 Método e composição farmacêutica para regular a concentração de lipídios

Country Status (27)

Country Link
US (3) US6124309A (pt)
EP (1) EP0858336B1 (pt)
JP (1) JPH11515025A (pt)
KR (2) KR100449604B1 (pt)
CN (2) CN1217656C (pt)
AR (1) AR004527A1 (pt)
AT (1) ATE348607T1 (pt)
AU (1) AU720853B2 (pt)
BG (1) BG64018B1 (pt)
BR (1) BR9611410A (pt)
CZ (1) CZ127198A3 (pt)
DE (1) DE69636783T2 (pt)
EA (1) EA000514B1 (pt)
ES (1) ES2279526T3 (pt)
GE (1) GEP20001898B (pt)
HK (1) HK1016509A1 (pt)
HU (1) HUP9901865A3 (pt)
IL (1) IL123902A (pt)
IS (1) IS4720A (pt)
NO (1) NO981961L (pt)
NZ (2) NZ319906A (pt)
PL (1) PL186714B1 (pt)
RO (1) RO120816B1 (pt)
SK (1) SK284142B6 (pt)
UA (1) UA46069C2 (pt)
WO (1) WO1997016184A1 (pt)
ZA (1) ZA969187B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
SI1009400T1 (en) * 1997-08-29 2005-04-30 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
CA2309588A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
PL346980A1 (en) * 1998-09-30 2002-03-11 Warner Lambert Co Method for preventing or delaying catheter-based revascularization
CO5140104A1 (es) 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) * 1999-10-15 2001-04-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Composes anti-ischemiques
KR20020050257A (ko) * 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
NZ524406A (en) * 2000-09-01 2004-06-25 Sankyo Co Medicinal compositions containing HMG-CoA reductase inhibitor and ACAT inhibitor
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
AU2002211666A1 (en) 2000-10-11 2002-04-22 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
WO2002030882A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
WO2002030860A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
CA2425121A1 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
EP1485077A4 (en) * 2002-03-12 2007-07-18 Merck & Co Inc DRUGS COMBINATION THERAPY
EP1495034A2 (en) * 2002-04-10 2005-01-12 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) * 2002-04-12 2008-11-26 興和株式会社 新規なトロンボモジュリン発現促進剤
DK2404890T3 (en) * 2003-01-23 2017-10-16 Esperion Therapeutics Inc Hydroxyl compounds and compositions for controlling cholesterol and related uses
WO2005020996A1 (ja) 2003-08-29 2005-03-10 Kowa Co., Ltd. リピド・リッチ・プラークの安定化方法及び破裂予防方法
CA2546079A1 (en) * 2003-11-17 2005-05-26 Toyo Shinyaku Co., Ltd. Lipometabolism improver containing pine bark extract
CA2549995C (en) 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
EP1737465A4 (en) * 2004-04-19 2007-10-03 Univ Loma Linda COMPOSITION AND METHOD FOR REDUCING RENAL ISCHEMIC DAMAGE
TW200605890A (en) * 2004-07-28 2006-02-16 Sankyo Co Pharmaceutical compositions for inhibiting arteriosclerosis
WO2006046593A1 (ja) * 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited ２以上の置換基を有するベンゼン化合物
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
EP2018153B1 (en) 2006-04-26 2012-04-11 Rosemont Pharmaceuticals Ltd Liquid oral compositions
US20130254787A1 (en) 2006-05-02 2013-09-26 Invidi Technologies Corporation Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
CN103288702B (zh) * 2010-12-03 2015-09-16 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐的制备方法
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103304496A (zh) * 2012-03-08 2013-09-18 南京工业大学 一种合成申嗪霉素方法
WO2013171100A1 (en) 2012-05-16 2013-11-21 Joachim Hans Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
RU2022102472A (ru) 2015-03-13 2022-03-15 Эсперион Терапеутикс, Инк. Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2020257571A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
WO1994009774A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Biologically active compounds and process therefor
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Also Published As

Publication number Publication date
KR20040029459A (ko) 2004-04-06
CN1679953A (zh) 2005-10-12
PL186714B1 (pl) 2004-02-27
KR19990067270A (ko) 1999-08-16
JPH11515025A (ja) 1999-12-21
CZ127198A3 (cs) 1998-12-16
IS4720A (is) 1998-04-17
EP0858336B1 (en) 2006-12-20
HK1016509A1 (en) 1999-11-05
ES2279526T3 (es) 2007-08-16
CN1201389A (zh) 1998-12-09
AU7253996A (en) 1997-05-22
EP0858336A1 (en) 1998-08-19
DE69636783T2 (de) 2007-10-18
US6093719A (en) 2000-07-25
NZ319906A (en) 2000-02-28
DE69636783D1 (de) 2007-02-01
NZ512484A (en) 2003-02-28
SK284142B6 (sk) 2004-10-05
KR100449604B1 (ko) 2004-11-16
EA199800420A1 (ru) 1998-10-29
ZA969187B (en) 1997-05-29
BG102417A (en) 1999-01-29
RO120816B1 (ro) 2006-08-30
EA000514B1 (ru) 1999-10-28
BG64018B1 (bg) 2003-10-31
UA46069C2 (uk) 2002-05-15
SK55798A3 (en) 1999-06-11
HUP9901865A2 (hu) 1999-10-28
US6143755A (en) 2000-11-07
WO1997016184A1 (en) 1997-05-09
ATE348607T1 (de) 2007-01-15
PL326365A1 (en) 1998-09-14
NO981961L (no) 1998-05-04
NO981961D0 (no) 1998-04-30
CN1217656C (zh) 2005-09-07
HUP9901865A3 (en) 2000-06-28
US6124309A (en) 2000-09-26
AR004527A1 (es) 1998-12-16
GEP20001898B (en) 2000-01-05
AU720853B2 (en) 2000-06-15
IL123902A (en) 2003-01-12
IL123902A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
PT854880E (pt) Novos derivados de 5-o-desosaminil 6-o-metil eritronolido a metodo para a sua preparacao e a sua utilizacao na preparacao de produtos biologicamente activos
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
AR002370A1 (es) Método y aparato para la preparación de ácido tereftálico purificado
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9405765A (pt) Embalagem carregadora de artigos e matriz para sua formação
ATA900296A (de) Verwendung von n-glyoxylprolylesterverbindungen in arzneimitteln
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
BR9604959A (pt) Composição e método para o tratamento de desensibilização de dentes
BR9605395A (pt) Método para emulsificação contínua de gomas de orgaopolisiloxana
BR9610106A (pt) Uso de aminoácidos básicos e derivados para diminuir níveis de ceramida
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
PT1015421E (pt) Novos derivados de fenilamidina processo para a sua preparacao e sua utilizacao como medicamentos
BR9600145A (pt) Processo para obtenção de uma preparação de flavana-lignana composto de flavano-lignana medicamento e processo para sua preparação
FI96317C (fi) Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
FI972949A (fi) Lääkemuoto kollagenaasin vapauttamiseksi haavoihin ja sen valmistusmenetelmiä
BR9607110A (pt) Composição liquida estruturada aquosa e processo para sua preparação
EE03440B1 (et) Bioloogilise toimega bensotiasolooni etaanamiinid ja nende valmistamise protsess
FI961017A0 (fi) Erityisesti vedessä eläville organismeille tarkoitettu rehu, joka sisältää alhaisessa lämpötilassa sulavia lipidejä, ja menetelmä rehun valmistamiseksi
PT754680E (pt) Benzoil-guanidinas substituidas em posicao 4 por fluoroalquilo processo para a sua preparacao a sua utilizacao como medicamento bem como medicamento que as contem
BR9500068A (pt) Embalagem e método para sua preparação
FR2730242B1 (fr) Composition thermoplastique et procede de preparation
BR9205493A (pt) Composicao farmaceutica e processo para fabricacao de composicao farmaceutica
BR9506062A (pt) Compostos processo para sua preparação medicamento e composição farmacêutica

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NOS ARTIGOS 8 E 13 DA LPI NO 9.279 DE 14/05/1996.

B12B Appeal against refusal [chapter 12.2 patent gazette]